Chemaphor Announces Positive Results of Pilot Canine Clinical Trial of an Oximunol(TM) Supplement
01 Febrero 2010 - 3:00PM
Marketwired
Chemaphor (TSX VENTURE: CFR), a biotechnology company specializing
in the development of health products for enhancing and maintaining
the wellness of animals, is pleased to announce it has completed
its first clinical trial to evaluate the efficacy of an oral
Oximunol™ supplement in promoting overall health and well-being of
companion canines. The clinical trial, conducted by the Chemaphor
Nutrisciences Research Group in Charlottetown, Prince Edward
Island, found statistically significant improvement of coat quality
and reduction of shedding compared to untreated controls. In
addition, treated dogs showed a tendency to increased enjoyment of
walks.
The study consisted of a blinded, randomized clinical trial
involving forty six dogs recruited from the public. The animals
were randomly assigned to receive either the Oximunol™ supplement
(0.5 mg/kg body weight) or a placebo once daily over a period of
six months. The Oximunol™ supplement's potential benefit to canine
wellness was assessed by analyzing owner responses to standardized
questions regarding the health status of their pets before and
after the supplement period. A full report of the study is being
prepared for submission for publication in a peer-reviewed
journal.
With these positive results and the absence of any negative
effects upon the animals, Chemaphor is proceeding with additional
clinical efficacy studies, financially supported by an NRC IRAP
grant, that are designed to further define the Oximunol™
supplement's animal wellness benefits. At the same time, Chemaphor
is moving forward in executing its commercialization plan for the
launch of companion animal wellness products, including outsourcing
the manufacture of canine oral supplements and carrying out work to
have the Oximunol™ supplement meet global regulatory and animal
health partner needs. Discussions are underway with potential
marketing, sales and distribution partners to position Oximunol™
supplements as premium-value products targeted towards veterinary
and "pet boutique" sales channels.
"The successful outcome of the pilot trial, achieved with a low
level of supplementation, is an exciting first milestone in our
companion animal commercialization project announced in August
2009" said Dr. Paul Dick, CEO of Chemaphor. "The in vivo results in
the dogs support in a very practical way the in vitro laboratory
findings of the Oximunol™ supplement's effects upon immune
function, consistent with the Oximunol™ supplement "lending a
helping hand" in maintaining and enhancing animal health. This
achievement provides major impetus to the launch of our first
companion animal wellness product within a year."
About the Oximunol™ Supplement
The Oximunol™ supplement is a proprietary mixture containing
compounds found naturally in the plant world in minute amounts as
oxidized derivatives of carotenoids. The supplement is obtained via
the spontaneous, full oxidation of beta-carotene. Uses for the
Oximunol™ supplement and other oxidized carotenoid products are
protected by patents owned by Chemaphor in multiple jurisdictions.
Additionally, Chemaphor has filed patent applications directed to
products containing the Oximunol™ supplement and their use for
enhancing and maintaining the wellness of companion animals.
About Chemaphor
Chemaphor Inc. (http://www.chemaphor.com) is a research and
development company working in collaboration with strategic
partners to develop its platform of carotenoid-derived oxidation
compounds for commercialization at micronutrient-like levels in
products for global markets, focusing primarily on animal wellness,
including non-antibiotic feed additives for terrestrial and aquatic
species, and food supplements for companion animals.
Forward Looking Statements
This press release contains forward-looking statements
regarding, among other things, Chemaphor's beliefs, plans,
objectives, strategies, estimates, intentions and expectations.
Actual results and events may differ materially from those included
in, contemplated or implied by such forward looking statements for
a variety of reasons. When used in this press release, the words
"seek", "believe", "develop", "intends", "will", "may",
"potential", "should" and similar expressions are intended to be
among the statements that identify forward-looking statements.
Forward-looking statements are subject to inherent risks and
uncertainties including, but not limited to, market and general
economic conditions, the availability to attract and retain key
personnel, the availability and terms of financing, the scientific
and commercial viability of planned products, changes in
Chemaphor's relationship with its key suppliers and partners,
competitive factors, changes in regulatory environments affecting
Chemaphor's business, and the accuracy in management's assumptions.
This list is not exhaustive of the factors that may affect any of
Chemaphor's forward-looking statements. Investors and others should
carefully consider these and other factors and not place undue
reliance on these forward-looking statements. In addition, these
forward-looking statements relate to the date on which they were
made and Chemaphor disclaims and has no intention or obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise.
Contacts: Chemaphor Inc. Graham Burton 613-990-0969
g.burton@chemaphor.com Evolution Group Inc. Investor Relations
Sylvain Archambault President 1-866-703-4887
s.archambault@evolutiongrp.com
Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024